Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 18, Issue 5, Pages 358-378Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41573-019-0012-9
Keywords
-
Funding
- National Institutes of Health (NIH)
- CHDI Foundation
- Grace Science Foundation
Ask authors/readers for more resources
Adeno-associated virus (AAV) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. Recent advances in developing clinically desirable AAV capsids, optimizing genome designs and harnessing revolutionary biotechnologies have contributed substantially to the growth of the gene therapy field. Preclinical and clinical successes in AAV-mediated gene replacement, gene silencing and gene editing have helped AAV gain popularity as the ideal therapeutic vector, with two AAV-based therapeutics gaining regulatory approval in Europe or the United States. Continued study of AAV biology and increased understanding of the associated therapeutic challenges and limitations will build the foundation for future clinical success.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available